Nature Communications (Oct 2022)
A single arm phase Ib/II trial of first-line pembrolizumab, trastuzumab and chemotherapy for advanced HER2-positive gastric cancer
- Choong-kun Lee,
- Sun Young Rha,
- Hyo Song Kim,
- Minkyu Jung,
- Beodeul Kang,
- Jingmin Che,
- Woo Sun Kwon,
- Sejung Park,
- Woo Kyun Bae,
- Dong-Hoe Koo,
- Su-Jin Shin,
- Hyunki Kim,
- Hei-Cheul Jeung,
- Dae Young Zang,
- Sang Kil Lee,
- Chung Mo Nam,
- Hyun Cheol Chung
Affiliations
- Choong-kun Lee
- Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine
- Sun Young Rha
- Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine
- Hyo Song Kim
- Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine
- Minkyu Jung
- Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine
- Beodeul Kang
- Department of Medical Oncology, CHA Bundang Medical Center, CHA University
- Jingmin Che
- Sondang Institute for Cancer Research, Yonsei University College of Medicine
- Woo Sun Kwon
- Sondang Institute for Cancer Research, Yonsei University College of Medicine
- Sejung Park
- Sondang Institute for Cancer Research, Yonsei University College of Medicine
- Woo Kyun Bae
- Division of Hematology-Oncology, Department of Internal Medicine, Chonnam National University Medical School and Hwasun Hospital
- Dong-Hoe Koo
- Division of Hematology/Oncology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine
- Su-Jin Shin
- Department of Pathology, Yonsei University College of Medicine
- Hyunki Kim
- Department of Pathology, Yonsei University College of Medicine
- Hei-Cheul Jeung
- Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine
- Dae Young Zang
- Division of Hematology-Oncology, Department of Internal Medicine, Hallym University Medical Center, Hallym University College of Medicine
- Sang Kil Lee
- Division of Gastroenterology, Department of Internal Medicine, Yonsei University College of Medicine
- Chung Mo Nam
- Department of Preventive Medicine, Yonsei University College of Medicine
- Hyun Cheol Chung
- Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine
- DOI
- https://doi.org/10.1038/s41467-022-33267-z
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 12
Abstract
In patients with advanced gastric cancer (AGC), resistance to treatment with trastuzumab and cytotoxic chemotherapy remains high. Here, the authors report the results of a phase Ib/II clinical trial assessing the safety and clinical response to a quadruplet regimen of pembrolizumab, trastuzumab, capecitabine, and cisplatin as a first-line therapy for HER2-positive AGC.
